Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) Equity Ratio (2023 - 2025)

CG Oncology filings provide 3 years of Equity Ratio readings, the most recent being 0.95 for Q4 2025.

  • On a quarterly basis, Equity Ratio fell 2.15% to 0.95 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.95, a 2.15% decrease, with the full-year FY2025 number at 0.95, down 2.15% from a year prior.
  • Equity Ratio hit 0.95 in Q4 2025 for CG Oncology, up from 0.94 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.98 in Q1 2024 to a low of 0.62 in Q4 2023.
  • Median Equity Ratio over the past 3 years was 0.97 (2025), compared with a mean of 0.79.
  • Biggest five-year swings in Equity Ratio: surged 257.31% in 2024 and later dropped 3.04% in 2025.
  • CG Oncology's Equity Ratio stood at 0.62 in 2023, then surged by 257.31% to 0.97 in 2024, then decreased by 2.15% to 0.95 in 2025.
  • The last three reported values for Equity Ratio were 0.95 (Q4 2025), 0.94 (Q3 2025), and 0.96 (Q2 2025) per Business Quant data.